Monitoring heart health during breast cancer treatment
Part of Cancer, Heart & circulation, Injuries & trauma, Skin clinical trials.
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with breast cancer at stage I, II, or III (not stage IV/metastatic)
- Planning to receive chemotherapy and/or HER2-targeted therapy as part of your cancer treatment
- Baseline heart function (ejection fraction) is normal or near-normal (≥50%)
- No prior chemotherapy or other heart-toxic drugs
- No existing heart failure or serious heart disease
- Age 18 or older and able to consent and attend follow-up appointments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can spot early signs of heart damage from certain breast cancer treatments (anthracycline chemo or anti-HER2 drugs). The goal is to protect your heart while you get the cancer treatment you need.
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
This trial compares whether special heart imaging or blood tests better helps monitor heart safety while you receive HER2-targeted therapy (like trastuzumab, with or without pertuzumab) plus chemotherapy. It may help doctors catch early heart stress and choose the safest treatment plan for you.
This study tests whether careful blood pressure management can help protect the heart during certain types of chemotherapy (anthracyclines) for breast cancer. Participants will use a smart blood pressure device and may also do an exercise test.
This trial uses a special scoring system (ML Score) to predict if you might develop heart problems while receiving anthracycline chemotherapy or HER2-targeted therapies. It helps doctors decide on the best heart monitoring plan before starting treatment.
This study watches heart health in people starting immunotherapy (a cancer treatment that boosts the immune system) by checking blood samples for heart-related markers. It aims to find early signs of heart problems so they can be managed sooner.
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.